- Home
- MRCC vs IKT Comparison
MRCC vs IKT Comparison
Compare MRCC & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MRCC | IKT |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.8M | 240.1M |
| IPO Year | 2011 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MRCC | IKT |
|---|---|---|
| Price | $4.78 | $1.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 146.6K | ★ 2.2M |
| Earning Date | 03-05-2026 | 11-14-2025 |
| Dividend Yield | ★ 7.48% | N/A |
| EPS Growth | N/A | ★ 67.51 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.11 | $1.33 |
| 52 Week High | $7.92 | $2.46 |
Technical Indicators
Market Signals| Indicator | MRCC | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 39.01 | 48.12 |
| Support Level | $4.11 | $1.45 |
| Resistance Level | $6.91 | $2.10 |
| Average True Range (ATR) | 0.32 | 0.12 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 35.68 | 24.19 |
Price Performance
Historical ComparisonAbout MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.